(1)
PÉCS, Hungary and BUDAPEST, Hungary, March 04, 2021 (GLOBE NEWSWIRE) TurnSole Biologics (TurnSole) today announced the start of a Phase I/II open-label study for Azacytidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20-50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients in Severe Infection with Risk of Progression as Add-on Therapy to Standard of Care, continued with a Randomized, Controlled, Open-Label Adaptive Phase II part to Determine Efficacy and Safety.
Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. Severe illness can occur in otherwise healthy individuals of any age, but it predominantly occurs in adults with advanced age or underlying medical comorbidities.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and .
EpiPharma LLC; Cyclolab Plc.January 11, 2021 GMT
SZEGED, Hungary and BUDAPEST, Hungary, Jan. 11, 2021 (GLOBE NEWSWIRE) Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development company, today announced that the companies have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.